Orient Pharma Co (ROCO:4166) Moat Score: 0/10 (As of Jul. 08, 2026)


ROCO:4166 Orient Pharma Co Ltd ROCO:4166
61 GF Score
Price NT$27.20
GF Value NT$45.11
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Orient Pharma Co Moat Score?

Orient Pharma Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Orient Pharma Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Orient Pharma Co might have No Moat - No discernible moat.

Orient Pharma Co  (ROCO:4166) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Orient Pharma Co Moat Score Related Terms

ROCO:4166
61GF Score
Orient Pharma Co Ltd ROCO:4166
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.11. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • Moat Score: 0
  • GF Value™: NT$45.11 vs. price of NT$27.20 (39.7% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
61GF Score

Get the complete analysis for ROCO:4166

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.20
Price
NT$45.11
GF Value